S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.33 (+0.09%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   352.96 (+2.02%)
GOOGL   2,844.30 (+0.71%)
TSLA   774.39 (+2.75%)
AMZN   3,425.52 (+0.28%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.05 (+0.01%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
AMC   40.01 (+0.08%)
S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.33 (+0.09%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   352.96 (+2.02%)
GOOGL   2,844.30 (+0.71%)
TSLA   774.39 (+2.75%)
AMZN   3,425.52 (+0.28%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.05 (+0.01%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
AMC   40.01 (+0.08%)
S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.33 (+0.09%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   352.96 (+2.02%)
GOOGL   2,844.30 (+0.71%)
TSLA   774.39 (+2.75%)
AMZN   3,425.52 (+0.28%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.05 (+0.01%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
AMC   40.01 (+0.08%)
S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.33 (+0.09%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   352.96 (+2.02%)
GOOGL   2,844.30 (+0.71%)
TSLA   774.39 (+2.75%)
AMZN   3,425.52 (+0.28%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.05 (+0.01%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
AMC   40.01 (+0.08%)
NYSE:EW

Edwards Lifesciences Stock Forecast, Price & News

$120.07
-0.95 (-0.78 %)
(As of 09/24/2021 12:00 AM ET)
Add
Compare
Today's Range
$119.10
$120.90
50-Day Range
$102.91
$122.75
52-Week Range
$70.92
$123.27
Volume1.58 million shs
Average Volume2.45 million shs
Market Capitalization$74.84 billion
P/E Ratio51.53
Dividend YieldN/A
Beta1.08
30 days | 90 days | 365 days | Advanced Chart
Receive EW News and Ratings via Email

Sign-up to receive the latest news and ratings for Edwards Lifesciences and its competitors with MarketBeat's FREE daily newsletter.


Edwards Lifesciences logo

About Edwards Lifesciences

Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart, and Critical Care. The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques. The Surgical Structural Heart portfolio includes tissue heart valves and heart valve repair products for the surgical replacement or repair of a patient's heart valve. The Critical Care portfolio products through hemodynamic monitoring system measures a patient's heart function and fluid status in surgical and intensive care settings. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

2.20 out of 5 stars

Medical Sector

348th out of 1,351 stocks

Surgical Appliances & Supplies Industry

11th out of 26 stocks

Analyst Opinion: 2.3Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Edwards Lifesciences (NYSE:EW) Frequently Asked Questions

Is Edwards Lifesciences a buy right now?

18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last twelve months. There are currently 6 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Edwards Lifesciences stock.
View analyst ratings for Edwards Lifesciences
or view top-rated stocks.

What stocks does MarketBeat like better than Edwards Lifesciences?

Wall Street analysts have given Edwards Lifesciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Edwards Lifesciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Edwards Lifesciences' next earnings date?

Edwards Lifesciences is scheduled to release its next quarterly earnings announcement on Wednesday, October 20th 2021.
View our earnings forecast for Edwards Lifesciences
.

How were Edwards Lifesciences' earnings last quarter?

Edwards Lifesciences Co. (NYSE:EW) posted its quarterly earnings results on Thursday, July, 29th. The medical research company reported $0.64 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.55 by $0.09. The medical research company earned $1.38 billion during the quarter, compared to analyst estimates of $1.29 billion. Edwards Lifesciences had a trailing twelve-month return on equity of 29.73% and a net margin of 29.69%.
View Edwards Lifesciences' earnings history
.

How has Edwards Lifesciences' stock been impacted by Coronavirus?

Edwards Lifesciences' stock was trading at $65.79 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, EW shares have increased by 82.5% and is now trading at $120.07.
View which stocks have been most impacted by COVID-19
.

When did Edwards Lifesciences' stock split? How did Edwards Lifesciences' stock split work?

Shares of Edwards Lifesciences split on Friday, May 29th 2020. The 3-1 split was announced on Thursday, May 7th 2020. The newly created shares were issued to shareholders after the market closes on Monday, May 18th 2020. An investor that had 100 shares of Edwards Lifesciences stock prior to the split would have 300 shares after the split.

What guidance has Edwards Lifesciences issued on next quarter's earnings?

Edwards Lifesciences updated its third quarter 2021 earnings guidance on Thursday, August, 5th. The company provided earnings per share guidance of $0.500-$0.560 for the period, compared to the Thomson Reuters consensus estimate of $0.550. The company issued revenue guidance of $1.29 billion-$1.37 billion, compared to the consensus revenue estimate of $1.30 billion.

What price target have analysts set for EW?

18 analysts have issued 1 year price targets for Edwards Lifesciences' shares. Their forecasts range from $85.00 to $135.00. On average, they anticipate Edwards Lifesciences' share price to reach $118.44 in the next twelve months. This suggests that the stock has a possible downside of 1.4%.
View analysts' price targets for Edwards Lifesciences
or view top-rated stocks among Wall Street analysts.

Who are Edwards Lifesciences' key executives?

Edwards Lifesciences' management team includes the following people:
  • Michael A. Mussallem, Chairman & Chief Executive Officer
  • Scott B. Ullem, Chief Financial Officer & Vice President
  • Todd J. Brinton, Chief Scientific Officer & VP-Advanced Technology
  • Arnold A. Pinkston, Vice President & General Counsel
  • Linda J. Park, Secretary, VP & Associate General Counsel

What is Michael A. Mussallem's approval rating as Edwards Lifesciences' CEO?

389 employees have rated Edwards Lifesciences CEO Michael A. Mussallem on Glassdoor.com. Michael A. Mussallem has an approval rating of 90% among Edwards Lifesciences' employees.

What other stocks do shareholders of Edwards Lifesciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), The Home Depot (HD), salesforce.com (CRM), The Walt Disney (DIS), Visa (V), Johnson & Johnson (JNJ), QUALCOMM (QCOM), Micron Technology (MU) and CVS Health (CVS).

What is Edwards Lifesciences' stock symbol?

Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."

Who are Edwards Lifesciences' major shareholders?

Edwards Lifesciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.48%), Vanguard Group Inc. (7.75%), State Street Corp (4.13%), Bank of New York Mellon Corp (3.75%), Capital International Investors (3.21%) and Alliancebernstein L.P. (2.09%). Company insiders that own Edwards Lifesciences stock include Catherine M Szyman, Donald E Bobo Jr, Heisz Leslie Stone, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Michael A Mussallem, Nicholas J Valeriani, Robert WA Sellers and Scott B Ullem.
View institutional ownership trends for Edwards Lifesciences
.

Which institutional investors are selling Edwards Lifesciences stock?

EW stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Jackson Square Partners LLC, Renaissance Technologies LLC, BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp, Neuberger Berman Group LLC, Sumitomo Mitsui Trust Holdings Inc., Great West Life Assurance Co. Can, and AQR Capital Management LLC. Company insiders that have sold Edwards Lifesciences company stock in the last year include Catherine M Szyman, Donald E Bobo Jr, Heisz Leslie Stone, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Nicholas J Valeriani, and Scott B Ullem.
View insider buying and selling activity for Edwards Lifesciences
or view top insider-selling stocks.

Which institutional investors are buying Edwards Lifesciences stock?

EW stock was acquired by a variety of institutional investors in the last quarter, including Amundi, FMR LLC, First Trust Advisors LP, Capital International Investors, 1832 Asset Management L.P., Man Group plc, UBS Asset Management Americas Inc., and Lord Abbett & CO. LLC.
View insider buying and selling activity for Edwards Lifesciences
or or view top insider-buying stocks.

How do I buy shares of Edwards Lifesciences?

Shares of EW can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Edwards Lifesciences' stock price today?

One share of EW stock can currently be purchased for approximately $120.07.

How much money does Edwards Lifesciences make?

Edwards Lifesciences has a market capitalization of $74.84 billion and generates $4.39 billion in revenue each year. The medical research company earns $823.40 million in net income (profit) each year or $1.86 on an earnings per share basis.

How many employees does Edwards Lifesciences have?

Edwards Lifesciences employs 14,900 workers across the globe.

Does Edwards Lifesciences have any subsidiaries?

The following companies are subsidiares of Edwards Lifesciences: BMEYE, CAS Medical Systems, CardiAQ Valve Technologies, Edwards Lifesciences (Japan) Limited, Edwards Lifesciences AG, Edwards Lifesciences Holding B.V., Edwards Lifesciences Innovation Holding LLC, Edwards Lifesciences LLC, Edwards Lifesciences Services GmbH, Embrella Cardiovascular, Harpoon Medical, Myocor, Percutaneous Valve Technologies, Valtech Cardio, and Whitland Research.

When was Edwards Lifesciences founded?

Edwards Lifesciences was founded in 1958.

What is Edwards Lifesciences' official website?

The official website for Edwards Lifesciences is www.edwards.com.

Where are Edwards Lifesciences' headquarters?

Edwards Lifesciences is headquartered at ONE EDWARDS WAY, IRVINE CA, 92614.

How can I contact Edwards Lifesciences?

Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The medical research company can be reached via phone at (949) 250-2500 or via email at [email protected].


This page was last updated on 9/24/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.